FindTrial
Sign In

The effect of denosmab on osteoporosis related to Parkinson's disease and glucocorticoid-induced osteoporosis

The effect of denosmab on osteoporosis related to Parkinson's disease and glucocorticoid-induced osteoporosis - The effect of denosmab on neurological disorders

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000025056
Enrollment
40
Registered
2016-11-29
Start date
2016-10-30
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteoporosis, Parkinson&#39

Interventions

denosmab

Sponsors

The Jikei University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1)>= 40 to =< 85 years of age at the time of consent (2)Patients with osteoporosis related to Parkinson's disease (3)Patients with glucocorticoid-induced osteoporosis

Exclusion criteria

Exclusion criteria: (1)Current or previous use of denosumab (2)Patients with renal insufficiency (CCr <30ml/min) (3)Patients with hypocalcemia(serum calcium<8.4mg/dl) (4)Female patients who are pregnant, trying to become pregnant or nursing (lactating) an infant

Design outcomes

Primary

MeasureTime frame
-Change in BMD -Change in bone turnover markers -Change in bone quality-related markers—

Countries

Japan

Contacts

Public ContactShusaku Omoto

The Jikei University School of Medicine Department of Neurology

s-omoto@jikei.ac.jp03-3433-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026